

Literaturverzeichnis zum Fachartikel "Moderne Behandlung der juvenilen idiopathischen Arthritis (JIA)" von Gerd Horneff in „Praxis Physiotherapie“, Ausgabe 3/2011:

De Benedetti FB, Brunner H, Ruperto N et al. Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: Efficacy Data from the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial. *Arthritis Rheum* 2010; 62: S596

Föll D, Gerss Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, J, Stanevicha V, Mihaylova D, Ferriani V, Tsakalidou FK, Foeldvari I, Cuttica R, B Gonzalez, Ravelli A, Khubchandani R, S Oliveira, Armbrust W, Garay S, Vojinovic J, Nora X, Gamir ML, García-Consuegra J, L Lepore, Susic G, F Corona, Dolezalova P, Pistorio A, Martini A, Ruperto N, Roth J; Pädiatrische Rheumatologie International Trials Organisation (PRINTO) JAMA. 2010 Apr 7; 303 (13) :1266-1273

Giannini EH, Ilowite NT, Lovell DJ et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. *Arthritis Rheum.* 2010 Nov;62(11):3259-64

Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. *Ann Rheum Dis.* 2008 Apr 15. [Epub ahead of print]

Lotito AP, Campa A, Silva CA, Kiss MH, Mello SB. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. *J Rheumatol.* 2007 Apr;34(4):823-30

Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. *N Engl J Med* 2000;342: 763-9

Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. *Arthritis Rheum.* 2008 May;58(5):1496-504.

Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schontube M, Zink A. Long-term outcome in patients with juvenile idiopathic arthritis. *Arthritis Rheum.* 2002;46:2392-401

Nigrovic PA, Mannion M, Prince FH et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. *Arthritis Rheum.* 2010 Nov 4. [Epub ahead of print]

Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. *Rheumatology (Oxford).* 2011 Jan;50(1):214-21.

Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P: International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J Rheumatol.* 2004;31:390-2

Petty RE. Prognosis in children with rheumatic diseases: justification for consideration of new therapies. *Rheumatology* 1999; 38:739-42

Prince FH, Twilt M, Ten Cate R, Van Rossum MA, Armbrust W, Hoppenreijns EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. *Ann Rheum Dis.* 2008 Apr 15. [Epub ahead of print]

Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). *Ann Rheum Dis.* 2010 Dec 20. [Epub ahead of print]

Ruperto N, Lovell DJ, Goodman S, Reiff A, Jung L, Nemcova D, Jarosova K, Prieur A, Sandborg C, Joos R, Foeldari I, Gerloni V, Rovensky J, Bohnsack J, Minden K, Wagner Weiner L, Vehe R, Kuppertz H, Horneff G, Olson N, Medich J, Giannini EH, Martini A: 48 week data from the study of Adalimumab in Children with Juvenile Rheumatoid Arthritis (JRA). *EULAR Amsterdam* 21.-24.6.06, *Ann Rheum Dis* 2006;65 (Supple 1):56

Singh-Grewal D, Schneider R, Bayer N, Feldman BM: Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. *Arthritis Rheum* 2006; 5:1595-1601

Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, B Bica, Campos L, Häfner R, Hofer M, Ozen S, Huemer C, Bae SC, Sztajn bok F, O Arguedas, Foeldvari I, Huppertz HALLO, Gamir ML , Magnusson B, F Dressler, Cawkwell Uziel Y, van Rossum MA, Hollingworth P, G, A Martini, Ruperto N; Pädiatrische Rheumatologie International Trials Organisation (PRINTO). *Ann Rheum Dis*. 2010 Aug; 69 (8) :1479-83. Epub 2010 Jun 4.

Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T: Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. *Arthritis Rheum*. 2005; 52:818-825